Page 24 - Lupin

Lupin, Nichi-Iko to commercialise arthritis biosimilar in Japan

Etanercept is used in treatment of auto immune diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis and ankylosing spondylitis

Lupin launches drug to control postpartum hemorrhage after USFDA nod

Lupin's product is the generic equivalent of Novartis Pharmaceuticals Corp's Methergine

Lupin showing signs of revival under its second-generation leadership team

But the going is still tricky

Lupin gains on EIR from USFDA for Pithampur Unit 1

At 10:41 am; the stock was trading 3% higher at Rs 808 after rallied 7% to Rs 843 on the NSE in intra-day trade

Lupin extends gain as UK MHRA completes inspection at Goa unit

The stock was up 3% to Rs 798, extending its Monday's 5% surge on the BSE

Lupin stock in 2017 global worst-performer list, says Evaluate report

US Food and Drug Administration's warning letters to two Lupin plants in Goa and Indore in November was the main reason for the decline in the stock price

Lupin hits 52-week low on weak Q3 results

The stock hit 52-week low of Rs 782, down 2.5% in intra-day trade, extending its previous day's 6% decline on BSE

Lupin: Q3 shows further rise in US pricing pressure as net profit falls 65%

Gross profit margins fell to a 16-quarter low, pulling down earnings by 65% y-o-y

Lupin extends gain; up 5% in four trading sessions

The stock moved higher by nearly 2% to Rs 852, extending its past three days 3.5% gain on the BSE

Lupin gets USFDA warning for Goa & Pithampur plants, stock tanks 15%

While the company can continue to supply existing products to the US market, fresh approvals will be delayed.

Lupin tanks 17%, hits over 3-year low as USFDA issues warning letter

The stock tanked 15% to Rs 880 on the BSE, trading at its lowest level since January 1, 2014.

US sales pressure hurts Lupin again

Growth in other geographies points to a better second half

Lupin Q2 profit down 31% at Rs 455 cr, but slightly above consensus

The drugmaker profit came in at Rs 455 cr for the quarter ended Sept 30, compared with Rs 662 cr a year earlier

Lupin surges 7% post September quarter earnings

The stock has moved higher by 7% to Rs 1,074 after the company reported a consolidated net profit of Rs 455 crore in Q2FY18

Lupin gets US FDA nod for carbidopa tablets to treat Parkinson's disease

Carbidopa tablets, 25 mg had annual sales of approximately $21.9 million in the US

Lupin: Price erosion still a key concern

Recent acquisition & large product pipeline long-term growth drivers; price erosion in US to weigh on earnings

Lupin buys Symbiomix Therapeutics for $150 mn to boost women's health biz

US market contributes around 45% of Lupin's revenue and this is the drug maker's second big acquisition in US in the last 15 months

Lupin gains 3% on USFDA approval for generic Corgard tablets

The company has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.

Lupin appoints Jim Loerop to drive M&A, business development strategy

Loerop will hold the position of chief corporate development officer

Lupin taps external funding for R&D of biosimilars in FY18

Lupin will file biosimilar Etanercept in Europe and Japan in FY 2018 and has tied up with a financial company to fund research and development cost of the drug.Biosimilars are copies of innovative biologic drugs and are made from living cells. Lupin is partnering with an another firm for drug development given the high cost and risks in the process.Etanercept is indicated for treatment of rheumatoid arthritis and is a copy of Amgen's innovative drug Enbrel.At an investor conference in Mumbai last week Lupin's managing director Nilesh Gupta said the company was on track to file Etanercept in Europe and Japan in the current fiscal and is developing a pipeline of select biosimilar drugs. Gupta said that the company is actively partnering for first few products and is targeting a total market size of $ 19 billion.In 2014 Lupin tied up with drug maker Yoshido to help in clinical trials and commercialisation of biosimilars in Japanese market. But the company has been slow to hit the ...